Chemical structure of SP600125.
Western blot analysis of extracts from 293T cells, untreated or treated with anisomycin (25 μg/ml) for the indicated times either with or without SP600125 pre-treatment (50 μM, 40 min), using Phospho-JunB (Thr102/Thr104) (D3C6) Rabbit mAb #8053 (upper) or JunB (C37F9) Rabbit mAb #3753 (lower).
Western blot analysis of extracts from 293T cells, untreated or treated with anisomycin (25 μg/ml, 15 min) either with or without SP600125 pre-treatment (50 μM, 40 min), using Phospho-c-Jun (Ser73) (D47G9) XP® Rabbit mAb #3270 (upper) or c-Jun (60A8) Rabbit mAb #9165 (lower).
SP600125 is supplied as a lyophilized powder. For a 25 mM stock, reconstitute the 10 mg in 1.82 ml DMSO. Working concentrations and length of treatment can vary depending on the desired effect, but it is typically used as a pre-treatment at 25-50 μM for 15-45 minutes prior to treating with a stimulator. Soluble in DMSO at 65 mg/ml; poorly soluble in ethanol and water.
Store lyophilized or in solution at -20ºC, desiccated. Protect from light. In lyophilized form, the chemical is stable for 24 months. Once in solution, use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.
|Solubility||Soluble in DMSO at 65mg/ml.|
Novel, potent, and selective JNK-1,-2, and -3 inhibitor, SP600125 is an ATP-competetive inhibitor effective on a range of kinases and enzymes. In cells, SP600125 caused a dose-dependent inhibition of the phosphorylation of c-Jun, the expression of inflammatory genes IL-2, COX-2, TNF-α, IFN-γ, and blocked the activation and differentiation of primary human CD4 cell cultures (1). SP600125 has also demonstrated inhibitory effects on tumor cell proliferation, endothelial cell migration, and tumor growth as well as blocking tumor and endothelial cells in the G2 phase of the cell cycle (2).
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST's products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST's Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.